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Plasmodium falciparum infection
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Malaria, which is the result of Plasmodium falciparum infection, is a global health threat that resulted in 
655,000 deaths and 216 million clinical cases in 2010 alone. Recent phase 3 trials with malaria vaccine candidate 
RTS,S/AS01 (RTS,S) in children has demonstrated modest efficacy against clinical and severe malaria. RTS,S 
targets the pre-erythrocytic phase of the disease and induces high antibody titers against the P. falciparum 
circumsporozoite protein (CSP) and a moderate CD4+ T cell response. The individual contribution of these 
adaptive immune responses to protection from infection remains unknown. Here, we found that prophylac-
tic administration of anti-CSP mAbs derived from an RTS,S-vaccinated recipient fully protected mice with 
humanized livers from i.v.- and mosquito bite–delivered P. falciparum sporozoite challenge. Titers of anti-CSP 
that conveyed full protection were within the range observed in human RTS,S vaccine recipients. Increasing 
anti-CSP titers resulted in a dose-dependent reduction of the liver parasite burden. These data indicate that 
RTS,S-induced antibodies are protective and provide sterilizing immunity against P. falciparum infection when 
reaching or exceeding a critical plasma concentration.
Introduction
Plasmodium species have developed multiple strategies to evade 
and suppress host immunity, which makes treatment and vac-
cine development very difficult (1). During a blood meal, an 
infected mosquito injects around 100 sporozoites into the skin, 
from which the parasites migrate to the bloodstream and travel to 
the liver (2, 3). After invasion of a hepatocyte, the parasite enters 
the pre-erythrocytic stage, which lasts 6.5 days (4). The study of 
Plasmodium falciparum’s liver stage is hampered by the low in vitro 
infection rate of human or primate host cells and by the need for 
a specialized insectary to rear and infect Anopheles mosquitoes for 
the production of sporozoites. The development of a mouse model 
with fully functional human hepatocytes has made it possible to 
study the liver stage in a preclinical in vivo setting (5–11).
Several candidate malaria vaccines are in development, but 
most study results have been rather disappointing (12–15). In 
phase 3 clinical trials, the most advanced malaria vaccine candi-
date, RTS,S/AS01 (GSK Vaccines; referred to herein as RTS,S), has 
shown 31% and 50% protective efficacy against clinical malaria 
in infants (6–12 weeks old) and children (5–17 months old), 
respectively (16, 17). RTS,S is based on the hepatitis B surface 
antigen (HBsAg) and the P. falciparum circumsporozoite protein 
(CSP) antigen virus-like particle (VLP) platform (1). In vaccinated 
humans, RTS,S induces high IgG concentrations to the NANP 
CSP repeat region and CD4+ T cells that interfere with the ability 
of the malaria sporozoites to infect hepatocytes (pre-erythrocytic 
stage) (1, 18). The exact mechanism of protection is still unknown, 
and in vitro correlates of protection have not yet been defined. 
Although the titer of anti-CSP IgG is not an established correlate 
of protection, an association with efficacy has been observed in 
several trials (15, 19–23), and it is suggested that the protective 
threshold for anti-CSP IgG concentrations in plasma is >20 μg/ml 
(24). In addition, an independent and weaker association between 
CSP-specific CD4+ T cell responses and protection was observed in 
2 phase II trials of RTS,S vaccines (21, 23).
Results and Discussion
To evaluate the protective efficacy of anti-CSP IgG in the absence 
of any confounding (i.e., T cell–mediated) factors, we administered 
varying doses of 3 human anti-CSP mAbs (designated Mal1C, 
Mal2A, and Mal3B) into humanized uPA-SCID mice before expo-
sure to P. falciparum. The human mAbs recognizing the NANP 
repeat region of CSP were derived from a subject vaccinated with 
RTS,S, as described previously (25). uPA-SCID mice were trans-
planted with cryopreserved primary human hepatocytes, all from 
the same lot, as described previously (5). The capacity of anti-
CSP mAbs to interact with sporozoites and inhibit their motility 
and cell traversal has previously been examined in vitro using a 
gliding assay (26) and an inhibition of sporozoite invasion assay 
(27, 28). The RTS,S-induced anti-CSP mAb Mal1C dose-depend-
ently inhibited gliding motility, with complete inhibition at 
1,000 EU/ml (Figure 1, A, C, and D). In the inhibition of sporozo-
ite invasion assay, parasites were added to wells containing HepG2 
or Huh7.5 cells. The frequency of parasites invading Huh7.5 and 
HepG2 cells (27) was comparable (Figure 1, B, E, and F). Since both 
assays allow for a long interaction time between antibody and 
sporozoite, one may wonder whether antibody concentrations 
that inhibit sporozoite functions in vitro are also effective in vivo, 
when antibodies and sporozoites can only interact during the brief 
passage from the mosquito bite to the liver (29).
To examine whether human anti-CSP mAbs are capable of 
preventing in vivo infection with P. falciparum sporozoites, 
13 humanized uPA-SCID mice were injected i.p. with PBS, and 
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17 mice were given varying doses of the anti-CSP mAb Mal1C: 
2 mg (n = 11), 200 μg (n = 3), and 20 μg (n = 3). The following day, 
plasma concentrations of circulating mAbs were measured using 
a validated and standardized ELISA (25). Immediately thereaf-
ter, mice were challenged either via i.v. injection of 150,000 
sporozoites (7 PBS, 6 Mal1C) or by exposing each mouse to 
20 P. falciparum–infected mosquitoes that were allowed to feed 
for 20 minutes (6 PBS, 11 Mal1C) (12). 5 days after challenge, 
mice were euthanized, and their livers were divided into 12 stan-
dardized sections. From each of these fragments, 25 mg was used 
to determine the human hepatocyte content and the P. falciparum 
liver load using quantitative RT-PCR (qPCR; L. Foquet, unpub-
lished observations, and refs. 30, 31). Regardless of infection 
route, all PBS-treated mice were infected with P. falciparum, and all 
mice pretreated with 2 mg Mal1C were protected (Table 1). Anti-
CSP plasma concentrations (geometric mean titer [GMT]) mea-
sured immediately before challenge were 3,421.5 and 3,133.4 EU/
ml in the i.v.- and mosquito bite–infected groups, respectively. 
After injection of 200 μg Mal1C, 2 of 3 mice were protected 
from infection. Antibody concentrations measured in the pro-
tected mice before infection were 139.7 and 273.1 EU/ml. The 
single unprotected mouse had an anti-CSP titer of 230.0 EU/ml 
and showed a much lower liver parasite burden than sham-treated 
mice (29.4 P. falciparum/106 human hepatocytes; Table 1). 
Liver parasite burden after treatment with 20 μg mAb in 3 mice 
showed minimal reduction compared with sham-treated animals. 
Anti-CSP mAb concentrations in these mice were 31.5, 23.7, and 
13.1 EU/ml (Table 1). Next, we tested whether 2 additional mAbs 
are able to prevent P. falciparum infection when administered in a 
dose corresponding to serum concentrations achievable by RTS,S 
vaccination (18, 32). Both Mal2A (HV3-HD3-HJ4:KV3-KJ2) and 
Mal3B (HV3-HD1-HJ6:KV1-KJ1) were different from Mal1C 
(HV3-HD3-HJ4:KV2-KJ2), as determined by sequence analy-
sis of VH:VL pairs (33). Groups of 3 mice were injected i.p. with 
400 μg of Mal1C, Mal2A, or Mal3B and challenged the next day 
by infected mosquito bites (Table 1). The anti-CSP plasma con-
centrations (GMT) measured before infection were 668.1, 723.1, 
and 868.4 EU/ml, respectively. As a control, 1 humanized mouse 
was injected with PBS and 1 with 400 μg of a control mAb direct-
ed against HBsAg, as anti-HBsAg antibodies are also induced by 
RTS,S. All mice treated with the anti-CSP mAbs were protected 
against infection, whereas both control mice were infected at day 
5 after challenge.
Previous research showed that passive transfer of antibodies 
directed against the repeat region of P. berghei CSP is capable of 
arresting P. berghei sporozoite motility within the skin of mice 
after mosquito challenge (34). Moreover, i.p. administration to 
human hepatocyte SCID mice of 2.5 mg of an anti-CSP mAb that 
cross-reacts with P. falciparum and P. berghei (Pf 49 1B2.2) reduced 
the number of infected human hepatocytes after i.v. injection of 
180,000 P. falciparum sporozoites, but sterile protection was not 
achieved (35). Here, we found that human anti-CSP mAbs derived 
from an RTS,S vaccinee were able to prevent infection of human 
liver uPA-SCID mice by P. falciparum when injected prior to para-
site challenge, regardless of infection route (i.v. or mosquito bite). 
The short contact time of antibodies with parasites after non- 
natural i.v. injection of sporozoites can conceal the protective 
effect of antibodies with lower binding affinity that may prove 
effective when the parasites are delivered via mosquito bite.
The anti-CSP concentrations measured immediately before 
parasite challenge and induced by administration of 400 μg 
of Mal1C, Mal2A, and Mal3B (Table 1) were in the same range 
as those previously measured in RTS,S vaccine trials using the 
same quantification method (25). The lower vaccine efficacy 
Figure 1
In vitro analysis of functional effects of RTS,S vaccine–induced mAbs on P. falciparum sporozoites. (A and B) A gliding motility assay (A) and an 
inhibition of sporozoite invasion assay (B; HepG2 and Huh7.5 cells) were performed after preincubation with different concentrations of Mal1C. 
Data represent mean ± SD from triplicate wells. (C and D) Gliding assay. Shown are images of the trails produced by sporozoites in the absence 
(C) and presence (D) of anti-CSP mAbs (1,000 EU/ml). (E and F) Inhibition of sporozoite invasion assay. (E) Merged image showing extracellular 
(red and green) and intracellular (green) parasites. Nuclei were stained with DAPI (blue). (F) Additional overlay with a light microscopic image 
shows the cell membrane. Original magnification, ×63.
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observed in field trials may be due to a progressive decline 
in antibody titer during the follow-up period. Indeed, after 
12 months, a 95% reduction of anti-CSP titer was observed, and 
antibody concentrations may drop below the level required to 
convey sterilizing immunity (36). Our results demonstrated 
that preventing natural P. falciparum infection of humanized 
mice could be achieved by passive transfer of mAbs induced by 
RTS,S vaccination of a malaria-naive volunteer. The sterilizing 
immunity transferred to the humanized mice provides a proof 
of principle that anti-CSP antibodies induced by RTS,S are able 
to prevent P. falciparum infection of the liver. These findings fur-
ther suggest that the protective efficacy of the RTS,S vaccine can 
possibly be improved by increasing the magnitude and persis-
tence of the CSP-specific antibody response.
Table 1
Prevention of infection by administration of different RTS,S vaccine–induced mAbs
Anti-CSP mAb (dose) Mouse ID Human albumin Liver repopulation Weight Preinfection titer Liver parasite burden Positive 
  (mg/ml) (%) (g) (EU/ml)A (Pf/106 HuHEP) samples
i.v. challengeB
PBS B647L 2.4 31.1 12.1 <50 422.8 2 of 12
PBS K1458RL 3.5 33.2 9.7 <50 251.6 4 of 12
PBS B627 6.8 33.5 11.8 <50 11,991.8 12 of 12
PBS B625R 3.1 34.7 18.9 <50 3,261 12 of 12
PBS B647RL 6 37.9 11.7 <50 3,233.2 12 of 12
PBS B673L 3.9 38.7 12.1 <50 26.9 2 of 12
PBS B644L 6.9 59.7 10.4 <50 2,505.3 12 of 12
Mal1C (2 mg) B698 6.6 51.3 14.4 1,522.9 0 0 of 12
Mal1C (2 mg) B701L 3.7 40.1 9.6 3,053.1 0 0 of 12
Mal1C (2 mg) B627R 4.6 32.6 12.3 3,333.9 0 0 of 12
Mal1C (2 mg) K1447L 2.5 27.7 11.2 3,513.8 0 0 of 12
Mal1C (2 mg) K1443 3.1 34.9 11.1 3,816.0 0 0 of 12
Mal1C (2 mg) K1447 4.9 47.6 12.2 4,553.6 0 0 of 12
Mosquito blood meal challenge 1
PBS K1468L 4.9 37 16.5 <5 890.7 6 of 12
PBS K1478 2.8 38.4 14.2 <5 664.6 4 of 12
PBS K1484L 5.2 55.9 15.1 <5 1,906.4 10 of 12
PBS K1482L 3.8 33.1 9.5 <50 3,637.6 12 of 12
PBS K1482 2.9 36.2 10.1 <50 2,909.4 12 of 12
PBS K1468L 9.4 52.5 13.8 <50 1,966.1 11 of 12
Mal1C (20 μg) K1477RL 7.2 61.2 11 13.1 543.5 8 of 12
Mal1C (20 μg) B722 3.2 36.3 13.6 23.7 1,353.2 3 of 12
Mal1C (20 μg) B673 3.7 38.3 13.4 31.5 150.3 3 of 12
Mal1C (200 μg) B685 3.9 42.3 16.3 139.7 0 0 of 12
Mal1C (200 μg) K1479L 3.3 30.9 15.3 230.0 29.4 2 of 12
Mal1C (200 μg) K1464L 6.6 33.1 13.5 273.1 0 0 of 12
Mal1C (2 mg) B664RL 6.4 51.3 14.9 2,311.5 0 0 of 12
Mal1C (2 mg) B710R 3 43.5 14.5 2,813.6 0 0 of 12
Mal1C (2 mg) B674LL 3.3 36.6 11.1 3,017.2 0 0 of 12
Mal1C (2 mg) B674L 4.5 33.9 11.5 4,030.2 0 0 of 12
Mal1C (2 mg) K1475 9.2 62.9 7 5,929.1 0 0 of 12
Mosquito blood meal challenge 2
PBS K1622RL 1.9 29.9 11.3 <5 623 7 of 12
Anti-HBsAg (400 μg) K1651L 7 42.7 12.1 <5C 4,938.6 11 of 12
Mal1C (400 μg) K1670 2.8 34.4 14.5 518.1 0 0 of 12
Mal1C (400 μg) B894R 2.1 34.5 10.9 734.3 0 0 of 12
Mal1C (400 μg) B880 4.4 43.3 8.5 784.0 0 0 of 12
Mal2A (400 μg) K1617L 5.9 47.2 12.6 400.2 0 0 of 12
Mal2A (400 μg) B894 2.4 35.7 11.1 1,099.9 0 0 of 12
Mal2A (400 μg) B880R 4.2 44.2 9.2 859.1 0 0 of 12
Mal3B (400 μg) K1617RL 4.8 36.4 13.1 567.0 0 0 of 12
Mal3B (400 μg) B864L 2.8 29.2 11.8 926.0 0 0 of 12
Mal3B (400 μg) K1552 2.1 38.7 10.2 1,247.3 0 0 of 12
Pf/106 HuHEP, P. falciparum per 106 human hepatocytes. ADepending on dilution, detection limit was 5 or 50 EU/ml. B150,000 sporozoites. CTiter was 
1.65 × 106 mIU/ml.
Downloaded from http://www.jci.org on February  3, 2016.   http://dx.doi.org/10.1172/JCI70349
brief report
 The Journal of Clinical Investigation   http://www.jci.org   Volume 124   Number 1   January 2014 143
Methods
Further information can be found in Supplemental Methods 
and Supplemental Table 1, available online with this article; 
doi:10.1172/JCI70349DS1.
Generation of humanized mice. Humanized uPA-SCID mice were generated 
as described previously (5).
Generation of human anti-CSP mAbs. The cell donor of the PBMCs used 
to generate the human anti-CSP mAb was selected from a clinical trial 
(MAL-080) evaluating the RTS,S vaccine at the Center for Vaccinology, 
Ghent University and Ghent University Hospital. Human B lymphocytes 
were immortalized as described previously (37). The mAb concentration 
was determined by measuring UV absorbance at 280 nm (1 mg/ml = 1.4 
absorbance units) and by anti-CSP ELISA (25).
mAb sequencing. Ig variable genes from 3 anti-CSP–producing hybrid-
omas were sequenced at the Centre for Medical Genetics of Ghent Uni-
versity, and obtained sequences were analyzed using IMGT/V-Quest 
(http://www.imgt.org/) to assign the variable gene family (33).
Anti-CSP ELISA. Antibodies specific for the CSP tandem repeat epitope 
were assessed by a validated, standard ELISA (25). At days 0 and 5, mice 
were bled, and plasma was stored at –80°C until analysis.
In vitro assays of anti-CSP antibody. Gliding assays and inhibition of 
sporozoite invasion assays were performed as described previously (38).
In vivo parasite challenge and prophylactic treatment experiments. 1 day prior 
to parasite challenge, chimeric uPA-SCID mice were injected i.p. with PBS, 
anti-HBsAg mAb, or mAbs specifically targeting the P. falciparum CSP. The 
following day, all animals were challenged with sporozoites, either via bites 
by infected mosquitos or via injection of parasites into the retro-orbital 
venous sinus. Anopheles stephensi mosquitoes were reared at Radboud Uni-
versity Medical Centre and infected according to previously described stan-
dard procedures (39).
Isolation and detection of P. falciparum DNA and human hepatocyte DNA by qPCR. 
5 days after infection, mice were euthanized by cervical dislocation, and their 
livers were stored at 4°C until analysis. P. falciparum DNA levels were quanti-
fied using a highly sensitive qPCR assay (30). To assess the degree of repopu-
lation with human hepatocytes of the chimeric livers, and to normalize the 
P. falciparum copy numbers, we used qPCR as previously described (31).
Statistics. Data are shown as mean ± SD. Analysis were performed using 
GraphPad Prism.
Study approval. All procedures were approved by the Animal Ethics 
Committee of the Faculty of Medicine and Health Sciences of 
Ghent University.
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